Menopause hormone therapy started in your 50s does more good than harm, and a patch avoids the clot risk

Evidence check, September 29, 2026

The claim: "The fear of hormone therapy came from a misread study. For women in their 50s, the benefits outweigh the risks."

Our grade: Solid, for women under 60 or within 10 years of menopause. Randomized trials show large relief from hot flashes, fewer fractures and small risks at this age. Starting later, at 65 or 70, is a different story.

Nora is 51. Her last period was a year ago. She wakes up soaked at 3 a.m. most nights, has a hot flash in almost every meeting, and has stopped running because she's too tired. Her doctor offered hormone therapy. Nora remembers 2002, when her mother stopped her pills overnight after the news said they caused breast cancer and heart attacks.

So is it safe for Nora to take it?

The answer depends on four things the 2002 headlines skipped: how old the women in the big trial were, when they started, what form of estrogen they took, and which progestin came with it.

Where the claim came from

Mary Claire Haver, an OB-GYN, opened her podcast unPAUSED in October 2025 with an episode on the Women's Health Initiative, the big 2002 trial [1]. Her guests argued that it scared a generation of women off hormones and that "the fear was based on misinterpreted data." She makes the same case in her book The New Menopause.

The fear was real. Among US women past menopause, hormone therapy use fell from 26.9% in 1999 to 4.7% in 2020 [2]. In November 2025 the FDA started removing the boxed warnings, its strongest kind, about heart disease, breast cancer and dementia. On February 12, 2026, it approved the first six new labels [3]. The warning about uterine cancer stays for estrogen taken alone by women who still have a uterus [4]. That's why they also need a progestogen, a hormone that protects the uterus lining.

Clue one: the big trial tested older women on an older pill

The Women's Health Initiative randomized 27,347 women aged 50 to 79 to hormones or a placebo [5]. Their average age was 63, well past menopause. They took one pill: estrogen from horse urine, and for women with a uterus, a synthetic progestin called medroxyprogesterone.

In that group, hormones did raise the risk of stroke and clots. But the absolute numbers were small, and after 18 years, deaths were the same: 27.1% on hormones and 27.6% on placebo [6]. The trial's own leaders now say it supports starting hormone therapy before 60 for women with bothersome symptoms. It doesn't support using it to prevent heart disease or dementia [5].

Clue two: timing changes the risk

A Cochrane review pooled 19 randomized trials with 40,410 women [7]. Across all ages, hormones didn't prevent heart attacks and raised the risk of stroke. But in women who started less than 10 years after menopause, deaths fell by 30% and heart disease by about half. Clots were still more common. The reviewers rated that evidence moderate.

Two smaller trials point the same way. In Denmark, 1,006 healthy women about 7 months past menopause got hormones or nothing for 10 years [8]. The hormone group had 16 heart attacks, heart failure admissions or deaths, against 33 without hormones, and no more cancer. In Los Angeles, 643 women took estradiol, the same estrogen the body makes, or a placebo for about 5 years [9]. In women within 6 years of menopause, the neck arteries thickened more slowly on estradiol. In women 10 or more years past it, there was no difference.

The brain follows the same pattern. In women 65 and older, estrogen plus progestin doubled the rate of probable dementia, from 22 to 45 cases per 10,000 women a year [10]. That's one reason the advice is to start early, not late.

Clue three: the form matters

Nora's biggest worry is a blood clot. On September 23, 2026, the BMJ published a nationwide study of Danish women aged 50 to 69 from 2003 to 2021 [11]. It compared 9,807 women who had a clot in a leg or lung, 18,460 who had a stroke and 11,974 who had a heart attack with about 200,000 matched women who didn't. It's an observational study, so it shows links, not proof.

Estrogen pills raised the risk of clots by about 60%. In real numbers that's 9 extra clots per 10,000 women a year, or 1 woman in about 1,055. Strokes rose by 6 and heart attacks by 3 per 10,000 a year. Stroke and heart attack risk were highest on more than 1 mg of estradiol a day for more than 5 years.

Estrogen through the skin, as a patch or gel, was not linked to more clots or strokes. The one exception: a patch combined with a progestogen taken part of each month was linked to about twice as many heart attacks, a less certain result. A 2019 UK study of 80,396 women with clots found the same thing: pills raised the risk, and patches and gels did not [12].

Clue four: breast cancer depends on the progestin

In the big trial, estrogen alone, given to women who'd had a hysterectomy, lowered breast cancer: 0.30% a year against 0.37% on placebo. Deaths from breast cancer were lower too [13]. That's the finding Haver's guests point to. Estrogen plus medroxyprogesterone raised it, from 0.36% to 0.45% a year, about 9 extra cases per 10,000 women a year, with no clear rise in deaths.

So back to Nora. She's 51 and a year past menopause, right in the window where the trials look best. Hot flashes fell by about 75% on hormones in 24 trials with 3,329 women [14], and fractures by about a quarter in the big trial [15]. If she uses a patch or gel with a progestogen to protect her uterus, her clot risk barely moves. Her main trade-off is a small rise in breast cancer risk, which she can weigh with her doctor.

Our grade

The case for the other side: the heart benefit in early starters comes from subgroups and small trials, and the biggest trial wasn't designed to test it. The patch results are observational; women who get patches may differ from women who get pills. Estrogen plus a progestin still raises breast cancer risk a little, and no trial has followed women who start in their 50s for decades.

What would change the grade: a large randomized trial of estradiol patches started around menopause, followed for heart attacks, dementia and breast cancer.

What this means for you

• If you're under 60 or within 10 years of your last period and hot flashes or poor sleep are wearing you down, ask your doctor about hormone therapy. At your age, the trials say the benefits usually win.
• Ask about a patch or gel instead of a pill. In two large studies, pills raised clot risk slightly and patches and gels did not.
• If you have a uterus, you need a progestogen too. Ask which one; the risks differ by type.
• Don't start hormones after 65 to protect your heart or memory. The trials found more harm than good.
• Hormones aren't safe for everyone. A past breast cancer, blood clot, stroke or liver disease usually rules them out; ask your doctor.
• Keep lifting weights and eating enough protein; they help you hold on to muscle at any age, with or without hormones.

What's next

This is the second article in our Hormones series, after testosterone therapy for men. We'll update this page as the FDA approves the rest of the new labels. For keeping muscle and bone as you age, see how much protein you need at your age.

Sources

1. Haver MC, Bluming A, Tavris C. The truth about estrogen: what the Women's Health Initiative got wrong. unPAUSED podcast, premiere episode, October 2025. https://thepauselife.com/blogs/the-unpaused-podcast/the-truth-about-estrogen-what-the-womens-health-initiative-got-wrong-with-dr-avrum-bluming-dr-carol-tavris
2. Yang L, Toriola AT. Menopausal hormone therapy use among postmenopausal women. JAMA Health Forum, 2024. 13,048 US women, repeated national surveys, 1999 to 2020. https://doi.org/10.1001/jamahealthforum.2024.3128
3. US Food and Drug Administration. FDA approves labeling changes to menopausal hormone therapy products. Press release, February 12, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-labeling-changes-menopausal-hormone-therapy-products
4. US Department of Health and Human Services. Fact sheet: FDA initiates removal of black box warnings from menopausal hormone replacement therapy products. November 10, 2025. https://www.hhs.gov/press-room/fact-sheet-fda-initiates-removal-of-black-box-warnings-from-menopausal-hormone-replacement-therapy-products.html
5. Manson JE, Crandall CJ, Rossouw JE, et al. The Women's Health Initiative randomized trials and clinical practice: a review. JAMA, 2024. 68,132 women in the trials, 27,347 in the hormone trials, up to 20 years. https://doi.org/10.1001/jama.2024.6542
6. Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women's Health Initiative randomized trials. JAMA, 2017. 27,347 women aged 50 to 79, randomized, placebo-controlled, 18 years of follow-up. https://doi.org/10.1001/jama.2017.11217
7. Boardman HM, Hartley L, Eisinga A, et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev, 2015. 19 randomized trials, 40,410 women. https://doi.org/10.1002/14651858.CD002229.pub4
8. Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ, 2012. 1,006 women aged 45 to 58, randomized, open-label, 10 years of treatment, 16 years of follow-up. https://doi.org/10.1136/bmj.e6409
9. Hodis HN, Mack WJ, Henderson VW, et al. Vascular effects of early versus late postmenopausal treatment with estradiol. N Engl J Med, 2016. 643 women, randomized, placebo-controlled, median 5 years. Funded by the National Institute on Aging. https://doi.org/10.1056/NEJMoa1505241
10. Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study. JAMA, 2003. Women aged 65 and older, randomized, placebo-controlled, about 4 years. https://doi.org/10.1001/jama.289.20.2651
11. Berggreen J, Pourhadi N, Wood-Kurland H, et al. Contemporary menopausal hormone therapy and thrombotic disease: nationwide nested case-control study. BMJ, 2026. Danish women aged 50 to 69, 2003 to 2021; 9,807 clots, 18,460 strokes, 11,974 heart attacks and 201,205 matched controls; observational. https://doi.org/10.1136/bmj-2026-100688
12. Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ, 2019. 80,396 UK women with clots and 391,494 controls, observational. https://doi.org/10.1136/bmj.k4810
13. Chlebowski RT, Anderson GL, Aragaki AK, et al. Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the Women's Health Initiative randomized clinical trials. JAMA, 2020. 27,347 women, randomized, placebo-controlled, more than 20 years of follow-up. https://doi.org/10.1001/jama.2020.9482
14. MacLennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev, 2004. 24 randomized trials, 3,329 women, 3 months to 3 years. https://doi.org/10.1002/14651858.CD002978.pub2
15. Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA, 2003. 16,608 women, randomized, placebo-controlled, average 5.6 years. https://doi.org/10.1001/jama.290.13.1729